RT Journal Article
SR Electronic
T1 Estimating the burden of SARS-CoV-2 in France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.20.20072413
DO 10.1101/2020.04.20.20072413
A1 Salje, Henrik
A1 Kiem, Cécile Tran
A1 Lefrancq, Noémie
A1 Courtejoie, Noémie
A1 Bosetti, Paolo
A1 Paireau, Juliette
A1 Andronico, Alessio
A1 Hozé, Nathanaël
A1 Richet, Jehanne
A1 Dubost, Claire-Lise
A1 Strat, Yann Le
A1 Lessler, Justin
A1 Bruhl, Daniel Levy
A1 Fontanet, Arnaud
A1 Opatowski, Lulla
A1 Boelle, Pierre-Yves
A1 Cauchemez, Simon
YR 2020
UL http://medrxiv.org/content/early/2020/04/27/2020.04.20.20072413.abstract
AB France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17th March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 2.6% of infected individuals are hospitalized and 0.53% die, ranging from 0.001% in those <20y to 8.3% in those >80y. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 3.3 to 0.5 (84% reduction). By 11 May, when interventions are scheduled to be eased, we project 3.7 million (range: 2.3-6.7) people, 5.7% of the population, will have been infected. Population immunity appears insufficient to avoid a second wave if all control measures are released at the end of the lockdown.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge financial support from the Investissement d’Avenir program, the Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases program (Grant ANR-10-LABX-62-IBEID), Santé Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005) and European Union V.E.O and RECOVER projects. HS would also like to acknowledge support from the European Research Council (No. 804744).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data than can be made available will be put on a GitHub link